Luspatercept - Acceleron Pharma/Celgene Corporation

Drug Profile

Luspatercept - Acceleron Pharma/Celgene Corporation

Alternative Names: ACE-536

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation
  • Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Beta-thalassaemia; Myelodysplastic syndromes
  • Phase II Anaemia; Myelofibrosis
  • No development reported Sickle cell anaemia

Most Recent Events

  • 02 Aug 2018 Acceleron plans the phase III COMMANDS trial for Myelodysplastic syndromes (First-line therapy) in the third quarter of 2018
  • 09 Jul 2018 The phase III BELIEVE met its primary and secondary endpoints
  • 28 Jun 2018 Celgene and Acceleron announces intention to submit NDA and MAA to US FDA and EMA for Myelodysplastic syndromes and Beta-thalassaemia in first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top